Search Patents
  • RECOMBINANT VECTORS ENCODING CHIMERIC CORONAVIRUS SPIKE PROTEINS AND USE THEREOF
    Publication number: 20240000920
    Abstract: The present invention provides recombinant vectors encoding a chimeric coronavirus spike protein. The present invention further provides new immunogenic compositions and vaccines comprising these recombinant vectors. Methods of administering these immunogenic compositions and vaccines to animal subjects, including humans, felines, and avians, to protect them against coronaviruses also are included. Methods of making the immunogenic compositions and vaccines alone or in combinations with other protective agents are provided too.
    Type: Application
    Filed: November 11, 2021
    Publication date: January 4, 2024
    Applicant: Intervet Inc.
    Inventors: Martijn Alexander Langereis, Ad De Groof, Paul Vermeij, Berend Jan Bosch
  • CLEAVING PRE-FUSION STATE SARS-COV-2 SPIKE PROTEIN
    Publication number: 20220227842
    Abstract: Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2.
    Type: Application
    Filed: April 28, 2021
    Publication date: July 21, 2022
    Inventors: Yang Xiang, Yan Tan
  • ANTIBODIES AGAINST SARS-COV-2 SPIKE PROTEIN
    Publication number: 20220213176
    Abstract: The present disclosure provides human antibodies and fragments thereof having binding specificity to the SARS-CoV-2 spike protein's receptor binding domain (RBD). The antibodies and fragments have strong affinity and potent neutralization ability against the SARS-CoV-2 virus and various mutant forms. Also provided are trimeric antibodies which have further enhanced neutralization capabilities. The antibodies and fragments thus may be used for preventing or treating SARS-CoV-2 viral infection or detecting the presence of the virus in a sample.
    Type: Application
    Filed: March 23, 2022
    Publication date: July 7, 2022
    Inventors: Peixiang Ma, Guang Yang, Richard A. Lerner, Min Qiang, Hou Wang
  • HUMAN ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AGAINST CORONAVIRUS SPIKE PROTEIN
    Publication number: 20230312689
    Abstract: It is an object of the present invention to provide antibodies against coronavirus (SARS-CoV-2). It is also an object of the present invention to provide a pharmaceutical composition against coronavirus infection using the antibody. According to the present invention, an antibody or antigen-binding fragment thereof that binds to the receptor-binding domain present in the spike protein of coronavirus and is capable of neutralizing the coronavirus, and a pharmaceutical composition for the prevention or treatment of coronavirus infection containing the antibody or antigen-binding fragment, are provided.
    Type: Application
    Filed: July 9, 2021
    Publication date: October 5, 2023
    Applicants: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, The University of Tokyo
    Inventors: Shuzo MATSUSHITA, Yu KAKU, Takeo KUWATA, Yoshihiro KAWAOKA, Masaki IMAI, Seiya YAMAYOSHI
  • Binding agents to pre-fusion state SARS-CoV-2 spike protein
    Patent number: 11421019
    Abstract: Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: August 23, 2022
    Inventors: Yang Xiang, Yan Tan
  • Cleaving pre-fusion state SARS-CoV-2 spike protein
    Patent number: 11746142
    Abstract: Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: September 5, 2023
    Assignee: ABCLONAL SCIENCE, INC.
    Inventors: Yang Xiang, Yan Tan
  • Non-integrating comprising mutant RT/IN proteins and the SARS-CoV-2 spike protein
    Patent number: 11129890
    Abstract: The present invention is directed to recombinant lentiviral particles that array the SARS-CoV-2 spike (S) protein on their surface (“SARS-CoV-2 S Protein Lentiviral Particles”), and that optionally comprise an additional copy of a polynucleotide encoding the SARS-CoV-2 spike (S) protein in their viral genome, and to methods for the production of such lentiviral particles. The invention particularly pertains to such SARS-CoV-2 S Protein Lentiviral Particles that have been engineered to be incapable of mediating the integration of their lentiviral genome into the chromosomes of infected cells and/or to be incapable of mediating the reverse transcription of their lentiviral genome. The present invention is also directed to “SARS-CoV-2 S Protein Lentiviral Vaccine” pharmaceutical compositions that comprise such SARS-CoV-2 S Protein Lentiviral Particles.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: September 28, 2021
    Assignee: Vigene Biosciences, Inc.
    Inventor: Zairen Sun
  • FUNCTIONAL LIGANDS TO SARS-COV-2 SPIKE PROTEIN
    Publication number: 20220396795
    Abstract: The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to targets, such as viruses (e.g. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)), and/or antigens thereof (e.g. Spike protein and/or its subunits).
    Type: Application
    Filed: May 25, 2021
    Publication date: December 15, 2022
    Inventors: GEORGE JACKSON, GARAM LEE, JASMINE KUAR, ALEXANDER CHIU, RAFAL DRABEK
  • ANTIBODIES CONJUGATED OR FUSED TO THE RECEPTOR-BINDING DOMAIN OF THE SARS-COV-2 SPIKE PROTEIN AND USES THEREOF FOR VACCINE PURPOSES
    Publication number: 20240010739
    Abstract: SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality. The inventors produced an antibody that is directed against a surface antigen (i.e. CD40) of an antigen presenting cell (i.e. dendritic cell) wherein the heavy chain was conjugated to the receptor-binding domain of the Sars-Cov-2 spike protein for its use as vaccine. In particular, the inventors show that said vaccine induces circulating Ab-secreting hu-B cells, elicits S-specific IgG+ hu-B cells, elicits the expansion of central memory CD4+ hu-T cells and the emergence of effector memory CD4+ T cells, elicits the expansion of central memory CD8+ hu-T cells at and the emergence of effector memory CD8+ T cells at and finally induces Stem-cell like memory hu-CD8+ T cells.
    Type: Application
    Filed: November 10, 2021
    Publication date: January 11, 2024
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris (APHP), Baylor Research Institute, Universite Paris Est Creteil Val De Marne
    Inventors: Yves LEVY, Gérard ZURAWSKI, Mireille CENTLIVRE, Sandra ZURAWSKI, Véronique GODOT
  • ANTIBODIES TARGETING THE SPIKE PROTEIN OF CORONAVIRUSES
    Publication number: 20240117011
    Abstract: Disclosed are monoclonal antibodies, antigen binding fragments, and bi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies.
    Type: Application
    Filed: February 4, 2022
    Publication date: April 11, 2024
    Applicant: The U.S.A., as Represented by the Secretary, Department of Health and Human Services
    Inventors: John Misasi, Lingshu Wang, Chaim Aryeh Schramm, John R. Mascola, Daniel Cesar Douek, Nancy J. Sullivan, Amy Ransier Henry, Tongqing Zhou, Peter D. Kwong, Wei Shi, Yi Zhang, Eun Sung Yang, Mario Roederer, Rosemarie Diana Mason, Amarendra Pegu, Julie E. Ledgerwood
  • SINGLE DOMAIN ANTIBODIES TARGETING SARS CORONAVIRUS SPIKE PROTEIN AND USES THEREOF
    Publication number: 20230391852
    Abstract: Polypeptides that specifically bind the spike (S) protein of human coronavirus, selected from six camel VHH single domain antibody phage display libraries, are described. The S protein-specific polypeptides disrupt binding of the SARS-CoV-2 and/or SARS-CoV S protein to the cellular receptor ACE2, which is important for neutralization of the virus. Use of the S protein-specific polypeptides for the diagnosis and treatment of SARS-CoV-2 and/or SARS-CoV is described.
    Type: Application
    Filed: October 26, 2021
    Publication date: December 7, 2023
    Applicant: The U.S.A., as Represented by the Secretary, Department of Health and Human Services
    Inventors: Mitchell Ho, Jessica Diana Hong
  • ANTI-SARS-COV-2 SPIKE PROTEIN ANTIBODIES AND METHODS OF USE
    Publication number: 20230192820
    Abstract: The invention provides anti-SARS-CoV-2 spike (S) protein antibodies and methods of using the same.
    Type: Application
    Filed: May 5, 2021
    Publication date: June 22, 2023
    Inventors: Yang WANG, Mark S.J. KLEMPNER, Qi LI, Monir EJEMEL
  • Coronavirus Spike Protein-Specific Antibody and Use Thereof
    Publication number: 20230417748
    Abstract: Provided are a coronavirus spike (S) protein-specific antibody and use thereof.
    Type: Application
    Filed: November 5, 2021
    Publication date: December 28, 2023
    Inventors: Dong-Sik KIM, Sua LEE, Shin A JANG, Jihoon KANG, KI Joon CHO, Soo Bin PARK, Young Woo HAN, Hyemi NAM, Mi Young OH, Jee Boong LEE, Jihye RYU, Mun Kyung KIM, Jeewon LEE
  • RECOMBINANT SPIKE ECTODOMAIN PROTEINS, COMPOSITIONS, VECTORS, KITS, AND METHODS FOR IMMUNIZING AGAINST AVIAN INFECTIOUS BRONCHITIS VIRUS
    Publication number: 20190046634
    Abstract: Disclosed are recombinant spike ectodomain proteins, compositions, vectors, kits, and methods for inducing an immune response against avian infectious bronchitis virus (IBV). In particular, the recombinant proteins, compositions, vectors, kits, and methods relate to, include, and/or utilize a soluble, multimerized form of the (IBV) spike (S) protein ectodomain. The recombinant proteins, compositions, vectors, kits, and methods may be utilized to immunize poultry against disease associated with IBV infection or to protect poultry from IBV infection.
    Type: Application
    Filed: August 9, 2018
    Publication date: February 14, 2019
    Applicant: Auburn University
    Inventors: Vicky L. van Santen, Haroldo E. Toro
  • Recombinant spike ectodomain proteins, compositions, vectors, kits, and methods for immunizing against avian infectious bronchitis virus
    Patent number: 10772953
    Abstract: Disclosed are recombinant spike ectodomain proteins, compositions, vectors, kits, and methods for inducing an immune response against avian infectious bronchitis virus (IBV). In particular, the recombinant proteins, compositions, vectors, kits, and methods relate to, include, and/or utilize a soluble, multimerized form of the (IBV) spike (S) protein ectodomain. The recombinant proteins, compositions, vectors, kits, and methods may be utilized to immunize poultry against disease associated with IBV infection or to protect poultry from IBV infection.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: September 15, 2020
    Assignee: Auburn University
    Inventors: Vicky L. van Santen, Haroldo E. Toro
  • COMPOSITIONS AND METHODS FOR DETECTING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) VARIANTS HAVING SPIKE PROTEIN MUTATIONS
    Publication number: 20220290221
    Abstract: Methods for the rapid detection of the presence of variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that contain mutations in the Spike (S) protein gene in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting SARS-CoV-2 variants containing S gene mutations and kits are provided that are designed for the detection of SARS-CoV-2 variants containing S gene mutations.
    Type: Application
    Filed: March 11, 2022
    Publication date: September 15, 2022
    Inventors: Chitra Manohar, Marcel R. Fontecha, Christopher David Santini, Eugene Spier, Jingtao Sun, Michelle Elizabeth Yee, Kalyani Mangipudi
  • Methods for producing and using IgY antibodies targeting the middle east respiratory syndrome coronavirus spike protein to treat or prevent MERS-CoV infection
    Patent number: 11319382
    Abstract: Chicken egg yolk antibodies (IgY Abs) specific to the Middle Eastern Respiratory Syndrome coronavirus spike (MERS-CoV S) protein demonstrate efficacy against MERS-CoV infection. The S-specific IgY Abs (anti-S IgY) are produced by injecting chickens with purified a recombinant MERS-CoV S protein, S1 subunit, or an S1 fragment. The purified anti-S IgY specifically bind to the MERS-CoV S protein and inhibit infection. In vitro neutralization of the IgY Abs against MERS-CoV was achieved in cell lines and in a human-transgenic mouse model treated with a pharmaceutical composition comprising the anti-S IgY. Viral antigen-positive cells in treated mice were reduced, compared to the adjuvant-only controls. Moreover, lung cells of anti-S IgY-treated mice showed significantly reduced inflammation, compared to the controls. Efficient neutralization of MERS-CoV infection is demonstrated both in vitro and in vivo using the anti-S IgY Abs.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: May 3, 2022
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Esam Ibraheem Azhar, Sherif Ali El-Kafrawy, Aymn Talat Abbas, Ashraf Abdu Tabil
  • Canine Respiratory Coronavirus (Crcv) Spike Protein, Polymerase and Hemagglutinin/Esterase
    Publication number: 20070248616
    Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g. Quebec and LY138) and human coronavirus strain OC43. The CRCV spike, polymerase and hemagglutinin/esterase cDNA and protein partial sequences are listed in FIGS. (1) to (4), (13) and (14).
    Type: Application
    Filed: July 1, 2003
    Publication date: October 25, 2007
    Inventors: John Brownlie, Victoria Chalker, Kerstin Erles
  • MONOCLONAL ANTIBODY AGAINST SPIKE S1 PROTEIN OF SARS-CoV-2 AND USE THEREOFOF
    Publication number: 20220056111
    Abstract: The disclosure provides rabbit monoclonal antibodies against the spike S1 protein of SARS-CoV-2 and uses thereof. The antibody comprises: a VH CDR1 selected from the group consisting of SEQ ID NO: 1-7; a VH CDR2 selected from the group consisting SEQ ID NO: 8-14; a VH CDR3 selected from the group consisting of SEQ ID NO: 15-21; a VL CDR1 selected from the group consisting SEQ IDN NO: 22-28; a VL CDR2 selected from the group consisting of SEQ ID NO: 29-35; and a VL CDR3 selected from the group consisting of SEQ ID NO: 36-42. The antibodies can be used for a rapid test or screening of SARS-CoV-2 infection. The antibodies can also be used for treating SARS-CoV-2 infection.
    Type: Application
    Filed: August 11, 2021
    Publication date: February 24, 2022
    Inventors: Hai WU, Yang LOU
  • Canine respiratory coronavirus (CRCV) spike protein, polymerase and hemagglutinin/esterase
    Patent number: 7776340
    Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (eg Quebec and LY138) and human coronavirus strain OC43. The CRCV spike, polymerase and hemagglutinin/esterase cDNA and protein partial sequences are listed in FIGS. (1) to (4), (13) and (14).
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: August 17, 2010
    Assignee: The Royal Veterinary College
    Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles
Narrow Results

Filter by US Classification